Better Coronavirus Stock: Regeneron or Eli Lilly?

There's a lot of demand for potential COVID-19 treatments from Regeneron (NASDAQ: REGN) and Eli Lilly (NYSE: LLY) if they can be proven safe and effective in clinical trials that are taking place right now. Regeneron has applied lessons learned during the development of an Ebola virus treatment candidate, REGN-EB3, to its attempt to treat COVID-19 patients, and temporarily protect healthy people at risk from infection. Earlier this year the FDA agreed to give REGN-EB3 a priority review after it provided a significantly stronger mortality benefit in a head-to-head study against other antiviral treatment candidates.